Investor Optimism Abounds SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) But Growth Is Lacking

When close to half the companies in Germany have price-to-earnings ratios (or "P/E's") below 18x, you may consider SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) as a stock to potentially avoid with its 22.2x P/E ratio. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's as high as it is.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

SCHOTT Pharma KGaA could be doing better as its earnings have been going backwards lately while most other companies have been seeing positive earnings growth. One possibility is that the P/E is high because investors think this poor earnings performance will turn the corner. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.

Check out our latest analysis for SCHOTT Pharma KGaA

Keen to find out how analysts think SCHOTT Pharma KGaA's future stacks up against the industry? In that case, our free report is a great place to start.

Is There Enough Growth For SCHOTT Pharma KGaA?

There's an inherent assumption that a company should outperform the market for P/E ratios like SCHOTT Pharma KGaA's to be considered reasonable.

Retrospectively, the last year delivered a frustrating 2.4% decrease to the company's bottom line. This has soured the latest three-year period, which nevertheless managed to deliver a decent 17% overall rise in EPS. So we can start by confirming that the company has generally done a good job of growing earnings over that time, even though it had some hiccups along the way.

Turning to the outlook, the next three years should generate growth of 15% each year as estimated by the eleven analysts watching the company. That's shaping up to be materially lower than the 17% per annum growth forecast for the broader market.

With this information, we find it concerning that SCHOTT Pharma KGaA is trading at a P/E higher than the market. Apparently many investors in the company are way more bullish than analysts indicate and aren't willing to let go of their stock at any price. Only the boldest would assume these prices are sustainable as this level of earnings growth is likely to weigh heavily on the share price eventually.

What We Can Learn From SCHOTT Pharma KGaA's P/E?

Generally, our preference is to limit the use of the price-to-earnings ratio to establishing what the market thinks about the overall health of a company.

Our examination of SCHOTT Pharma KGaA's analyst forecasts revealed that its inferior earnings outlook isn't impacting its high P/E anywhere near as much as we would have predicted. Right now we are increasingly uncomfortable with the high P/E as the predicted future earnings aren't likely to support such positive sentiment for long. This places shareholders' investments at significant risk and potential investors in danger of paying an excessive premium.

Many other vital risk factors can be found on the company's balance sheet. Take a look at our free balance sheet analysis for SCHOTT Pharma KGaA with six simple checks on some of these key factors.

It's important to make sure you look for a great company, not just the first idea you come across. So take a peek at this free list of interesting companies with strong recent earnings growth (and a low P/E).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.